- Home
- IFRX vs LPTX Comparison
IFRX vs LPTX Comparison
Compare IFRX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- LPTX
- Stock Information
- Founded
- IFRX 2007
- LPTX 2011
- Country
- IFRX Germany
- LPTX United States
- Employees
- IFRX N/A
- LPTX N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IFRX Health Care
- LPTX Health Care
- Exchange
- IFRX Nasdaq
- LPTX Nasdaq
- Market Cap
- IFRX 117.8M
- LPTX 119.6M
- IPO Year
- IFRX 2017
- LPTX N/A
- Fundamental
- Price
- IFRX $1.15
- LPTX $0.34
- Analyst Decision
- IFRX Strong Buy
- LPTX Buy
- Analyst Count
- IFRX 2
- LPTX 2
- Target Price
- IFRX $9.00
- LPTX $8.00
- AVG Volume (30 Days)
- IFRX 337.7K
- LPTX 5.9M
- Earning Date
- IFRX 05-07-2025
- LPTX 03-26-2025
- Dividend Yield
- IFRX N/A
- LPTX N/A
- EPS Growth
- IFRX N/A
- LPTX N/A
- EPS
- IFRX N/A
- LPTX N/A
- Revenue
- IFRX $171,642.00
- LPTX N/A
- Revenue This Year
- IFRX $106.72
- LPTX N/A
- Revenue Next Year
- IFRX $66.89
- LPTX N/A
- P/E Ratio
- IFRX N/A
- LPTX N/A
- Revenue Growth
- IFRX 162.79
- LPTX N/A
- 52 Week Low
- IFRX $1.01
- LPTX $0.28
- 52 Week High
- IFRX $2.82
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- IFRX 38.70
- LPTX 33.17
- Support Level
- IFRX $1.01
- LPTX $0.28
- Resistance Level
- IFRX $1.30
- LPTX $0.65
- Average True Range (ATR)
- IFRX 0.13
- LPTX 0.05
- MACD
- IFRX 0.02
- LPTX 0.02
- Stochastic Oscillator
- IFRX 34.15
- LPTX 16.22
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .